Potential impact of acceleration of the pertussis vaccine primary series for infants

Pediatrics

Volumn 122, Issue 5, 2008, Pages 1021-1026

  Shinall Jr, Myrick C ^a   Peters, Timothy R ^b   Zhu, Yuwei ^a   Chen, Qingxia ^a   Poehling, Katherine A ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Infants; Pertussis; Preventive health care visits; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

AGE; ARTICLE; CHILD DEATH; CHILD HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; INFECTION RATE; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; UNITED STATES; VACCINATION; IMMUNIZATION; MORTALITY; POISSON DISTRIBUTION; PRACTICE GUIDELINE;

DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; POISSON DISTRIBUTION; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; WHOOPING COUGH;

EID: 58149149363     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-3025     Document Type: Article

References (42)

1. National Institute of Allergy and Infectious Diseases. The Jordan Report 20th Anniversary: Accelerated Development of Vaccines 2002. Bethesda, MD: National Institutes of Health; 2002
2. Cherry JD. The science and fiction of the "resurgence" of pertussis. Pediatrics. 2003;112(2):405-406
3. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. JAMA. 2003;290(22):2968-2975
4. Crowcroft NS, Andrews N, Rooney C, Brisson M, Miller E. Deaths from pertussis are underestimated in England. Arch Dis Child. 2002;86(5):336-338
5. Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child. 2003; 88(9):802-806
6. Sutter RW, Cochi SL. Pertussis hospitalizations and mortality in the United States, 1985-1988: evaluation of the completeness of national reporting. JAMA. 1992;267(3):386-391
7. Centers for Disease Control and Prevention. Pertussis: United States, 2001-2003. MMWR Morb Mortal Wkly Rep. 2005;54(50):1283-1286
8. Szilagyi PG, Griffin MR, Shone LP, et al. The impact of conjugate pneumococcal vaccination on routine childhood vaccination and primary care use in 2 counties. Pediatrics. 2006;118(4): 1394-1402
9. National Center for Immunization and Respiratory Diseases. National Immunization Survey: statistics and surveillance: 2004 table data. Available at: www.cdc.gov/vaccines/statssurv/default.htm. Accessed August 25, 2008
10. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;334(6):341-348
11. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five- component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996;334(6):349-355
12. Bisgard KM, Rhodes P, Connelly BL, et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics. 2005;116(2). Available at: www.pediatrics.org/cgi/content/ full/116/2/e285
13. American Academy of Pediatrics. Pertussis (whooping cough). In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006: 498-520
14. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;55(RR-17):1-37
15. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J. 2003;22(7):628-634
16. Centers for Disease Control and Prevention. Pertussis: United States, 1997-2000. MMWR Morb Mortal Wkly Rep. 2002;51(4):73-76
17. Centers for Disease Control and Prevention. Pertussis: United States, January 1992-June 1995. MMWR Morb Mortal Wkly Rep. 1995;44(28):525-528
18. Centers for Disease Control and Prevention. Pertussis deaths:United States, 2000. MMWR Morb Mortal Wkly Rep. 2002; 51(28):616-618
19. Wortis N, Strebel PM, Wharton M, Bardenheier B, Hardy IR. Pertussis deaths: report of 23 cases in the United States, 1992 and 1993. Pediatrics. 1996;97(5):607-612
20. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S. Births: final data for 2004. Natl Vital Stat Rep. 2006;55(1):1-101
21. Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol. 1990;131(2):373-375
22. Centers for Disease Control and Prevention. Impact of vaccines universally recommended for children: United States, 1990-1998. MMWR Morb Mortal Wkly Rep. 1999;48(12):243-248
23. André FE. Vaccinology: past achievements, present roadblocks and future promises. Vaccine. 2003;21(7-8):593-595
24. Arístegui J, Dal-Ré R, Díez-Delgado J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine. 2003;21(25-26):3593-3600
25. Cheng HK, Rajadurai VS, Amin Z, et al. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine. Southeast Asian J Trop Med Public Health. 2004;35(3):685-692
26. Centers for Disease Control and Prevention. Resurgence of pertussis: United States, 1993. MMWR Morb Mortal Wkly Rep. 1993;42(49):952-960
27. Christie CD, Marx ML, Marchant CD, Reising SF. The 1993 epidemic of pertussis in Cincinnati: resurgence of disease in a highly immunized population of children. N Engl J Med. 1994; 331(1):16-21
28. Brown GC, Kendrick PL. Serologic response of infants to a multiple vaccine for simultaneous immunization against diphtheria, pertussis, tetanus, and polio-myelitis, in relation to the presence of specific maternal antibody. Am J Public Health Nations Health. 1960;50(10):1529-1538
29. Provenzano RW, Wetterlow LH, Sullivan CL. Immunization and antibody response in the newborn infant, part I: pertussis inoculation within twenty-four hours of birth. N Engl J Med. 1965;273(18):959-965
30. Baraff LJ, Leake RD, Burstyn DG, et al. Immunologic response to early and routine DTP immunization in infants. Pediatrics. 1984;73(1):37-42
31. Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glezen WP. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis. 1993;168(3):647-656
32. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics. 1995;96(3):580-584
33. Di Sant'Agnese PA. Combined immunization against diphtheria, tetanus and pertussis in newborn infants, part III: relationship of age to antibody production. Pediatrics. 1949;3(3):333-344
34. Cherry JD, Chang SJ, Klein D, et al. Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis. 2004;39(11): 1715-1718
35. Heininger U, Cherry JD, Stehr K. Serologic response and anti- body-titer decay in adults with pertussis. Clin Infect Dis. 2004; 38(4):591-594
36. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect. 2006;53(2):106-113
37. Pavlopoulou ID, Syriopoulou V, Daikos GL, et al. Pertussis seroprevalence in different age groups in Greece. Scand J Infect Dis. 2007;39(1):14-18
38. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353(15):1555- 1563
39. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-3):1-34
40. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics. 2006;117(3):965-978
41. McNabb SJ, Jajosky RN, Hall-Baker PA, et al. Summary of notifiable diseases: United States, 2005. MMWR Morb Mortal Wkly Rep. 2007;54(53):1-92
42. Cortese MM, Baughman AL, Zhang R, Srivastava PU, Wallace GS. Pertussis hospitalizations among infants in the United States, 1993 to 2004. Pediatrics. 2008;121:484 -492